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Introduction: In the phase IV, open-label, single-arm study 
NCT01203917, first-line gefitinib 250 mg/d was effective and well 
tolerated in Caucasian patients with epidermal growth factor receptor 
(EGFR) mutation-positive non–small-cell lung cancer (previously 
published). Here, we report EGFR mutation analyses of plasma-
derived, circulating-free tumor DNA.
Methods: Mandatory tumor and duplicate plasma (1 and 2) baseline 
samples were collected (all screened patients; n = 1060). Preplanned, 
exploratory analyses included EGFR mutation (and subtype) sta-
tus of tumor versus plasma and between plasma samples. Post hoc, 
exploratory analyses included efficacy by tumor and plasma EGFR 
mutation (and subtype) status.
Results: Available baseline tumor samples were 1033 of 1060 (118 
positive of 859 mutation status known; mutation frequency, 13.7%). 
Available plasma 1 samples were 803 of 1060 (82 positive of 784 
mutation status known; mutation frequency, 10.5%). Mutation status 
concordance between 652 matched tumor and plasma 1 samples was 
94.3% (95% confidence interval [CI], 92.3–96.0) (comparable for 
mutation subtypes); test sensitivity was 65.7% (95% CI, 55.8–74.7); 
and test specificity was 99.8% (95% CI, 99.0–100.0). Twelve patients 
of unknown tumor mutation status were subsequently identified as 
plasma mutation-positive. Available plasma 2 samples were 803 of 
1060 (65 positive of 224 mutation status-evaluable and -known). 
Mutation status concordance between 224 matched duplicate plasma 
1 and 2 samples was 96.9% (95% CI, 93.7–98.7). Objective response 
rates are as follows: mutation-positive tumor, 70% (95% CI, 60.5–
77.7); mutation-positive tumor and plasma 1, 76.9% (95% CI, 65.4–
85.5); and mutation-positive tumor and mutation-negative plasma 
1, 59.5% (95% CI, 43.5–73.7). Median progression-free survival 
(months) was 9.7 (95% CI, 8.5–11.0; 61 events) for mutation-pos-
itive tumor and 10.2 (95% CI, 8.5–12.5; 36 events) for mutation-
positive tumor and plasma 1.
Conclusion: The high concordance, specificity, and sensitivity dem-
onstrate that EGFR mutation status can be accurately assessed using 
circulating-free tumor DNA. Although encouraging and suggesting 
that plasma is a suitable substitute for mutation analysis, tumor tissue 
should remain the preferred sample type when available.
Key Words: EGFR mutation, Gefitinib, non–small-cell lung cancer, 
Caucasian, Circulating-free tumor DNA.
(J Thorac Oncol. 2014;9: 1345–1353)
Successful analysis of epidermal growth factor receptor (EGFR) mutations in advanced non–small-cell lung cancer 
(NSCLC) has provided many patients with EGFR mutation-
positive disease with the opportunity to receive optimal, targeted 
treatments.1,2 Tumor tissue is considered the preferred definitive 
standard sample type for EGFR mutation analysis3; however, for 
many patients, this sample type is not available (~10–15% from 
author’s clinical experience, and ~23% in the United Kingdom 
in 2011).4 A molecular-based treatment decision in these 
patients can therefore be problematic, not only at diagnosis but 
also at progression, to detect resistance mutations (e.g., T790M) 
in those who experience disease progression after first-line treat-
ment with EGFR tyrosine kinase inhibitors (TKIs).
Consequently, focus has turned to evaluating the use 
of surrogate sample types for EGFR mutation analysis, the 
aim of which is to identify the molecular characteristics of 
tumors from patients who do not have tumor tissue samples.5–7 
One alternative sample type is circulating-free tumor DNA 
(ctDNA), which is obtained through less invasive methods to 
source tumor DNA, such as plasma or serum samples. The 
available evidence for the use of ctDNA for the analysis of 
EGFR mutations is encouraging, a brief review of which is 
given below.
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In 2009, results were published from a large Spanish 
study which assessed EGFR mutation detection in 164 ctDNA 
samples from the serum of patients with EGFR mutation-
positive NSCLC as determined from tumor tissue testing.8 
Peptide nucleic acid clamp analysis identified EGFR muta-
tions in 97 ctDNA samples, a sensitivity of 59.2%. A Chinese 
study of 35 matched ctDNA and tumor tissue samples also 
published in 2009 successfully analyzed all ctDNA samples 
using digital polymerase chain reaction (PCR).9 Subsequent to 
the publication of these studies, a review published by Aung et 
al.10 discussed the current status and future potential of EGFR 
mutation testing from ctDNA and concluded that plasma 
ctDNA would be a viable alternative/additional source of 
DNA, particularly as advances in PCR technology had allowed 
the analysis of point mutations in EGFR, KRAS, BRAF, and 
PIK3CA genes from ctDNA isolated from patients’ serum or 
plasma.11–14 The 2011 publication by Liu et al.15 reported the 
successful EGFR mutation analysis of 86 matched plasma-
derived ctDNA and formalin-fixed, paraffin-embedded 
samples using a Scorpion-amplification refractory mutation 
system (ARMS). Of the 40 tumor samples identified as EGFR 
mutation-positive, 27 were correctly identified in ctDNA, a 
sensitivity of 67.5%. More recently, EGFR mutation testing 
of 194 serum-derived ctDNA samples was undertaken as part 
of a preplanned, exploratory analysis of the Japanese subset of 
the IPASS study.5 EGFR mutations (tested using the ARMS-
based DxS EGFR mutation Test Kit [DxS, Manchester, UK]) 
were successfully detected in all 194 ctDNA samples, with 
sensitivity of 43.1%. Moreover, in the 22 patients where muta-
tions were identified in ctDNA and tumor samples, the muta-
tion subtypes were identical in 21 cases. Ongoing real-world 
studies are also evaluating the utility of plasma ctDNA-based 
EGFR mutation testing compared with tumor DNA. The non-
interventional ASSESS study (Europe and Japan)16 and inter-
ventional IGNITE study (Asia-Pacific region and Russia)17 are 
non-comparative studies of EGFR mutation status in patients 
with advanced NSCLC of adenocarcinoma and non-adeno-
carcinoma histologies. Concordance between EGFR mutation 
status obtained through tissue/cytology and blood (plasma)-
based testing is a primary and secondary objective of the 
ASSESS and IGNITE studies, respectively. Results from these 
large, international studies will help establish whether plasma 
is a suitable, less invasive sample type for reliably determining 
the EGFR mutation status of patients with advanced NSCLC, 
thus informing the use of this sample type in patients without 
available/evaluable tumor samples.
One study which has explored per-protocol the use of 
plasma ctDNA alongside the more traditional tumor tissue for 
EGFR mutation analysis is the phase IV, prospective, open-
label, multicenter, single-arm, first-line study of the EGFR 
TKI gefitinib in Caucasian patients with EGFR mutation-pos-
itive, advanced NSCLC (NCT01203917). The efficacy and 
tolerability results of this study have been published previ-
ously.18 Briefly, first-line gefitinib was effective in this patient 
population, as assessed by objective response rate (ORR; 70%, 
95% confidence interval [CI], 60.5–77.7%), and supported 
by disease control rate (91%), median progression-free sur-
vival (PFS, 9.7 mo), and median overall survival (19.2 mo).18  
First-line gefitinib was well tolerated, with adverse events 
consistent with the characterized tolerability/safety profile for 
gefitinib in previous studies.19–22
Patients with NSCLC initially entered the screening phase 
of the study (n = 1060), and eligible patients were progressed to 
enrollment on the basis of tumor tissue availability and a posi-
tive EGFR mutation status. Here, we report a comparison of 
baseline tumor EGFR mutation status in all screened patients 
with evaluable results for baseline plasma. Further analyses 
compared plasma-derived ctDNA EGFR mutation status in 
duplicate baseline plasma samples from the same patient to 
evaluate reliability of methodology in non-tumor samples. Post 
hoc, exploratory analyses of efficacy (ORR and PFS) accord-
ing to tumor-derived DNA and plasma-derived ctDNA EGFR 
mutation status (and mutation subtype) are also reported.
MATERIALS AND METHODS
Study Design and Patients
Full details of this study (NCT01203917) have been 
published previously.18 Briefly, the gefitinib follow-up mea-
sure study was a prospective, open-label, multicenter, single-
arm study to characterize the efficacy, safety, and tolerability 
of gefitinib (250 mg/d) as first-line treatment of Caucasian 
patients with activating, sensitizing, EGFR mutation-positive, 
locally advanced, or metastatic NSCLC. Patient eligibility cri-
teria have been published previously18 and included manda-
tory provision of tumor samples and duplicate plasma samples 
for EGFR mutation testing at baseline; in addition, optional 
plasma samples were collected at disease progression (see 
below for EGFR mutation subtype eligibility criteria).
All patients provided written, informed consent, includ-
ing provision for collection of tumor and plasma samples for 
biomarker analyses. Study approval was obtained from inde-
pendent ethics committees at each institution. The study was 
conducted in accordance with the Declaration of Helsinki, 
the International Conference on Harmonisation/Good 
Clinical Practice, applicable regulatory requirements, and 
AstraZeneca’s policy on bioethics.
Assessments
Tumor assessment by computed tomography scan was 
performed every 6 weeks. The primary end point of the study, 
ORR (complete response plus partial response) by investiga-
tor assessment, was determined by the Response Evaluation 
Criteria In Solid Tumors23 version 1.1. PFS (secondary end 
point; time from start of study treatment to date of objective 
tumor progression [excluding clinical deterioration without 
evidence of objective progression]) was also determined by 
Response Evaluation Criteria In Solid Tumors 1.1. Preplanned 
exploratory objectives included a comparison of baseline 
tumor EGFR mutation status with evaluable results for base-
line plasma, a comparison of plasma-derived ctDNA EGFR 
mutation status in duplicate baseline plasma samples (plasma 1 
and 2 samples), and a comparison of baseline and progression 
plasma samples, from the same patient. Post hoc exploratory 
analyses included efficacy of gefitinib according to tumor and 
plasma EGFR mutation (and mutation subtype) status.
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DNA Extraction and EGFR Mutation Analysis
One tumor sample (mandatory) and two plasma samples 
(mandatory; plasma 1 and plasma 2) were collected from each 
patient at baseline (screening) for DNA extraction and EGFR 
mutation analysis. An optional plasma sample was collected at 
disease progression.
Whole blood samples were collected into venous blood 
collection tubes using ethylenediaminetetraacetic acid as 
anticoagulant. Samples were mixed thoroughly and plasma 
isolated within 2 to 4 hours of sample collection by centrifu-
gation at approximately 2000 g for 10 minutes (at 4°C or room 
temperature for pre-chilled samples). Once isolated, plasma 
samples were centrifuged again (as above), before transferring 
into cryovials and freezing at −70°C within 4 hours of collec-
tion. Samples were not thawed until the time of processing.
A central laboratory (LabCorp, Durham, NC) per-
formed DNA extraction and mutation analysis of both the 
tumor and plasma samples. Tumor DNA was extracted using 
the Qiagen QIAamp DNA Mini Kit (Qiagen, Crawley, UK). 
whereas ctDNA was extracted from plasma using the Qiagen 
QIAamp Circulating Nucleic Acid Kit (Qiagen). Sample pro-
cessing details, including modifications to processes, are shown 
in Supplementary Appendix Table 1 (Supplementary Digital 
Content 1, http://links.lww.com/JTO/A638).
EGFR mutation status of all samples was assessed 
using a Scorpion ARMS-based EGFR mutation detection kit 
(Therascreen EGFR RGQ PCR kit; Qiagen, Crawley, UK), 
which detects 29 mutations across the EGFR gene. For tumor 
samples, all mutations in the kit were analyzed. Methodological 
and technical details for EGFR mutation testing, including 
modifications to tumor/ctDNA analysis kit instructions and data 
quality control details, are shown in Supplementary Appendix 
Table 1 (Supplementary Digital Content 1, http://links.lww.
com/JTO/A638). A comparison of the Qiagen kit used for 
ctDNA EGFR mutation analysis in the current study and the 
previous version of the DxS kit used in the IPASS study19,22 are 
shown in Supplementary Appendix Table 2 (Supplementary 
Digital Content 1, http://links.lww.com/JTO/A638).
EGFR mutation status was assigned to baseline tumor 
samples according to agreed eligibility criteria: positive, more 
than or equal to one activating, sensitizing EGFR mutation 
with no ineligible mutations; positive ineligible, more than 
or equal to one ineligible mutation (exon 20 point mutations 
T790M; S768I; exon 20 insertions, either alone or in combi-
nation with another ineligible mutation or a sensitizing muta-
tion [see Douillard et al.17 appendix]); negative, no mutations 
detected; and unknown, no mutation results available (exhaus-
tion of samples, poor quality, or low DNA yield).
Plasma samples were analyzed for exon 19 deletions, 
L858R point mutation, and the T790M point mutation only. 
The following EGFR mutation status was assigned to indi-
vidual plasma samples: positive, more than or equal to 1 muta-
tion (L858R, exon 19 deletions [19 different mutations], and 
T790M); negative, no mutations were detected; and unknown, 
no mutation results available (no sample or poor quality).
Statistical Analysis
Data were analyzed using a data cutoff (August 15, 
2012) at 6 months after the last patient had started study treat-
ment. ORR (primary end point) was calculated from inves-
tigator data and summarized in the full analysis set (FAS; 
all screened patients with an eligible, positive EGFR muta-
tion status who received ≥1 dose of gefitinib), with 95% CIs 
(Wilson score intervals). PFS was estimated with 95% CIs 
(FAS) using Kaplan-Meier methods and Greenwood’s for-
mula (Greenwood 1926)24 (PFS rates) and Brookmeyer and 
Crowley’s method (median PFS).
Baseline tumor and plasma 1 EGFR mutation status (over-
all and by mutation subtype), in patients in the screened popula-
tion who were evaluable for both samples, were compared with 
rates (percentages) and 95% CIs (Clopper-Pearson method) 
calculated for concordance, sensitivity, specificity, and positive- 
and negative-predictive value. Duplicate baseline plasma 1 and 
plasma 2 samples and baseline and progression plasma samples 
were compared, with rates and 95% CIs calculated.
RESULTS
Patients
Of 1060 patients screened from 13 countries, 1033 
(97.5%) provided baseline tumor samples. Of these, EGFR 
mutation status could be determined for 859 patients (81.0%), 
and 118 patients (11.1%) were assigned an eligible EGFR 
mutation-positive status (mutation frequency, 13.7%) and 
enrolled in the study from September 8, 2010, to February 15, 
2012; gefitinib treatment was started in 106 of these patients 
(FAS population) (Fig. 1). One additional patient of EGFR 
mutation-positive ineligible status was treated with gefitinib 
in error. Of the 201 patients (19%) for whom tumor EGFR 
mutation status could not be determined (unevaluable/unavail-
able), tissue was not provided from 27 patients (2.6%) who 
consented, and 174 patients (16.4%) could not be evaluated 
for EGFR mutation status (100 [9.4%] failed histopathology, 
42 [4.0%] yielded insufficient DNA, 2 [0.2%] failed EGFR 
mutation analysis, and 30 [2.8%] were not shipped from the 
study site in time). A flow diagram of the accountability of 
tumor samples is presented in Figure 2.
A total of 803 of 1060 screened patients (75.8%) provided 
duplicate baseline plasma 1 and 2 samples. Of these, EGFR 
mutation status could be determined using plasma 1 samples 
for 784 patients (74.0%), and 82 patients (7.7%) were assigned 
an EGFR mutation-positive status (mutation frequency, 10.5%). 
To achieve a similar measure of accuracy for analysis of plasma 
2 samples and avoid unnecessary sample use, EGFR mutation 
status was determined for 224 plasma 2 samples whose cor-
responding plasma 1 sample was EGFR mutation status-known 
(all EGFR mutation-positive plasma 1 for whom plasma 2 was 
available, and a matched number of EGFR mutation-negative). 
Of these 224 plasma 2 samples chosen for analysis, 65 were 
assigned an EGFR mutation-positive status.
Demographics and baseline characteristics by EGFR 
mutation status derived from baseline tumor samples (FAS 
population), plasma 1 samples, and plasma 2 samples are pre-
sented in Supplementary Appendix Table 3 (Supplementary 
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Digital Content 1, http://links.lww.com/JTO/A638) and were 
similar for all populations. Exon 19 deletions and L858R point 
mutations were the most commonly occurring mutations.
Comparison of EGFR Mutation Status in 
Matched Baseline Tumor and Plasma 1  
Samples (Screened Population)
Fewer patients were identified as having EGFR 
mutation-positive status using plasma 1-derived ctDNA 
(detection rate, 10.5%; 82 of 784 patients) than with tumor-
derived DNA (detection rate, 13.7%, 118 of 859 patients). 
Due to technical problems with tumor samples (e.g., low 
tumor content, poor sample quality, insufficient quan-
tity, poor/inappropriate fixation, no DNA), 201 of 1060 
screened patients (19.0%) had an unknown EGFR muta-
tion status; 12 of these patients were subsequently found to 
have a positive EGFR mutation status in their correspond-
ing plasma 1 samples.
A total of 652 patients provided matched baseline tumor 
and plasma 1 samples that were evaluable for EGFR mutation 
status using both sample types. A comparison of EGFR muta-
tion status between tumor and plasma 1 samples is shown in 
Table 1. Concordance between baseline tumor and plasma 1 
EGFR mutation status for patients evaluable for both samples 
was 94.3% (95% CI, 92.3–96.0), with a sensitivity of 65.7% 
(95% CI, 55.8–74.7) and specificity of 99.8% (95% CI, 99.0–
100.0). Positive-predictive value and negative-predictive value 
of EGFR mutation status detection between baseline tumor 
and plasma 1 samples for patients evaluable for both samples 
are also shown. A comparison of EGFR mutation status by 
mutation subtype for baseline tumor and plasma 1 samples 
is presented in Table 2. When analyzed by mutation subtype, 
concordance between baseline tumor and plasma 1 EGFR 
mutation status for patients evaluable for both samples was 
96.5% (95% CI, 94.8–97.8) for exon 19 deletions and 97.9% 
(95% CI, 96.4–98.8) for L858R point mutations; sensitivity 
FIgURE 1.  Patient flow diagram. aAll screened patients. Used to calculate the correlation between clinical characteristics 
and tumor EGFR mutation status and the comparison of EGFR mutation status between tumor DNA and plasma-derived 
circulating-free tumor DNA. bOne patient of EGFR mutation-positive ineligible status was treated in error and included in the 
evaluable-for-safety population. A total of 107 patients therefore started study treatment. cFull analysis set population. Used to 
summarize efficacy data and for the comparison of EGFR mutation status in plasma and tumor samples. dNumber of patients 
with EGFR mutation-positive tumors (n = 118) used as the denominator for the percentage calculation. eNumber of patients 
started on treatment (n = 107) used as the denominator for the percentage calculation. EGFR, epidermal growth factor receptor. 
Reproduced, in part, from Douillard et al.17 Br J Cancer 2014;110:55–62.
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was 67.6% (95% CI, 55.5–78.2) and 61.8% (95% CI, 43.6–
77.8), and specificity was 100.0% (95% CI, 99.4–100.0) and 
99.8% (95% CI, 99.1–100.0), respectively.
Of the 547 patients considered to have an EGFR muta-
tion-negative status by analysis of tumor DNA, one patient 
was considered to have an EGFR mutation-positive status 
by analysis of plasma 1 ctDNA, giving a false-positive rate 
of 0.2% (1 of 547). However, further investigation indicated 
that this was a false-positive result due to signal drift and 
was not a genuine positive amplification of the ctDNA (see 
Supplementary Appendix, Supplementary Digital Content 1, 
http://links.lww.com/JTO/A638, for further details).
Comparison of EGFR Mutation 
Status in Duplicate Baseline Plasma 
Samples (Screened Population)
Of the 803 screened patients who provided duplicate 
baseline plasma samples, 224 were evaluated and known for 
ctDNA EGFR mutation status. A total of 63 were identified 
with EGFR mutation-positive status in both samples, seven 
were EGFR mutation-positive in one plasma sample only, and 
154 were negative in both samples (Table 3). Concordance 
between duplicate baseline plasma sample EGFR mutation 
status (regardless of mutation status) for patients evaluable 
for both samples was 96.9% (95% CI, 93.7–98.7) (Table 3). 
A summary of EGFR mutation status in duplicate baseline 
plasma samples by mutation subtype for patients evaluable for 
both samples is presented in Table 4.
Comparison of EGFR Mutation Status 
in Baseline and Progression Plasma 
Samples (Screened Population)
A total of 12 patients provided matched baseline 
(plasma 1) and progression plasma samples. EGFR muta-
tion status concordance rate was 75.0% (95% CI, 42.8–94.5); 
mutation subtype results agreed in eight patients (caution is 
advised when interpreting these data due to small n num-
bers). Four patients had differences in EGFR mutation status: 
FIgURE 2.  Tumor sample flow diagram. EGFR, 
epidermal growth factor receptor.
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no mutations were detected in progression plasma ctDNA 
from three patients in which exon 19 deletions were detected 
in baseline plasma 1 ctDNA; one patient with an exon 19 
deletion in baseline plasma 1 ctDNA acquired an additional 
T790M mutation in progression plasma ctDNA.
Post Hoc Analysis of Efficacy of gefitinib 
According to Tumor and Plasma EGFR 
Mutation Status (FAS Population)
As of data cutoff, an objective response was seen in 
74 of 106 patients in the FAS population whose tumors were 
EGFR mutation-positive, with an ORR of 69.8% (95% CI, 
60.5–77.7) based on investigator assessment (n = 2 with com-
plete response; n = 72 with partial response) (Fig. 3).
For patients with matched tumor and plasma 1 samples, 
an ORR of 76.9% (95% CI, 65.4–85.5) was observed among 
those with a positive EGFR mutation result in both sample 
types (n = 50/65) (Fig. 3). An ORR of 59.5% (95% CI, 43.5–
73.7) was observed among the 22 of 37 patients found to be 
mutation-positive by tumor but mutation-negative by plasma. 
Results were also consistent when analyzed by mutation sub-
types: ORR for patients with both EGFR mutation-positive 
tumor and plasma 1 for exon 19 deletions (n = 45) 82.2% 
TABLE 1. EGFR Mutation Status Summary, Concordance, 
Sensitivity, Specificity, and Positive- and Negative-Predictive 
Value for Tumor vs. Plasma 1 Circulating-Free Tumor DNA 
Samples by EGFR Mutation Status (Screened Patients 
Evaluable for Both Samples, n = 652)
Plasma 1 EGFR 
Mutation Status, n
TotalPositive Negative
Tumor EGFR mutation status, na
  Positive 69 36 105
  Negative 1 546 547
  Total 70 582 652
n Rate, %
95% Confidence 
Interval
Concordance 652 94.3 92.3–96.0
Sensitivity 105 65.7 55.8–74.7
Specificity 547 99.8 99.0–100.0
Positive-predictive value 70 98.6 92.3–100.0
Negative-predictive value 582 93.8 91.5–95.6
aFor the comparison of tumor and plasma data, the tumor DNA mutation status was 
adjusted for the mutations analyzed in circulating-free tumor DNA from plasma (i.e., for 
exon 19 deletions, L858R point mutations and T790M point mutations only).
EGFR, epidermal growth factor receptor.
TABLE 2. EGFR Mutation Status Summary, Concordance, Sensitivity, Specificity, and Positive- and Negative-Predictive Value 
for Tumor vs. Plasma 1 Circulating-Free Tumor DNA Samples by EGFR Mutation Subtype (Screened Patients Evaluable for Both 
Samples, n = 652)
Plasma 1, n
Total
Positive: Exon 19  
Deletions Positive: L858R
Positive: L858R  
and T790M Negative
Tumor, n
  Positive: exon 19 deletions 48 0 0 23 71
  Positive: L858R 0 21 0 12 33
  Positive: L858R and T790M 0 0 0 1 1
  Negative 0 1 0 546 547
  Total 48 22 0 582 652
n Rate, % 95% Confidence Interval
Concordance
  Exon 19 deletions 652 96.5 94.8–97.8
  L858R 652 97.9 96.4–98.8
Sensitivity
  Exon 19 deletions 71 67.6 55.5–78.2
  L858R 34 61.8 43.6–77.8
Specificity
  Exon 19 deletions 581 100.0 99.4–100.0
  L858R 618 99.8 99.1–100.0
Positive-predictive value
  Exon 19 deletions 48 100.0 92.6–100.0
  L858R 22 95.5 77.2–99.9
Negative-predictive value
  Exon 19 deletions 604 96.2 94.3–97.6
  L858R 630 97.9 96.5–98.9
EGFR, epidermal growth factor receptor.
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(95% CI, 68.7–90.7) and L858R (n = 20) 65.0% (95% CI, 
40.8–84.6).
Median PFS for patients with matched tumor and 
plasma 1 samples that were positive for EGFR mutation in 
both sample types was 10.2 months (36 events; 95% CI, 
8.5–12.5) (Table 5), consistent with those patients who were 
EGFR mutation-positive by tumor, regardless of plasma 
ctDNA EGFR mutation status (median PFS, 9.7 mo [95% 
CI, 8.5–11.0]). When analyzed by mutation subtypes, median 
PFS for patients with matched tumor and plasma 1 samples 
that were positive in both sample types for exon 19 deletions 
(25 events) was 10.3 months (95% CI, 8.5–12.4), consis-
tent with the PFS for patients whose tumors were exon 19 
deletion-positive (41 events; median PFS, 9.6 mo; 95% CI, 
8.0–11.0). There were an insufficient number of events to 
assess the PFS of patients with samples that were L858R 
mutation-positive (tumor or ctDNA).
DISCUSSION
The gefitinib follow-up measure study18 is, to our 
knowledge, the first prospective, large-scale study of first-line 
gefitinib to be conducted in Caucasian patients with EGFR 
mutation-positive advanced NSCLC. Previously published effi-
cacy and tolerability results from the study show that first-line 
gefitinib is effective and well tolerated in this patient popula-
tion.18 The preplanned and exploratory biomarker analyses 
reported here show a high rate of concordance for EGFR muta-
tion status (including mutation subtypes) between tumor tissue 
DNA and plasma ctDNA and between duplicate plasma ctDNA 
samples. Tumor EGFR mutation status could not be determined 
(unevaluable/unavailable) for 19% of patient samples. Together, 
these results suggest that a single plasma-derived ctDNA sam-
ple may be considered appropriate for assessment of EGFR 
mutation status when tumor tissue is unavailable or exhausted.
The plasma ctDNA EGFR mutation analysis results 
reported here demonstrated 94.3% concordance, 99.8% speci-
ficity, and 65.7% sensitivity, an improvement on previous 
analysis of ctDNA, for example, in the IPASS study.5 This 
improvement may be due to a number of reasons, including 
different sample type (plasma versus serum), different DNA 
extraction method (the current study used a bespoke ctDNA 
extraction method), or a modified ARMS mutation detec-
tion kit. With regard to concordance between detection of 
EGFR mutations in matched tumor and plasma samples, a 
recent study of 111 Chinese patients with stage I–IV NSCLC 
reported 71.2% concordance, 35.6% sensitivity, and 95.5% 
specificity using enriched PCR and sequencing.25 Similarly, 
Yung et al.9 reported a specificity and sensitivity (using micro-
fluidics digital PCR) of EGFR mutation status with ctDNA 
and matched tumor samples from 35 Chinese patients with 
NSCLC of 100% and 92%, respectively.
When considering ctDNA sample EGFR mutation status 
as patient selection for EGFR TKI therapy, the results we have 
reported here suggest that use of this alternative sample type 
may be appropriate in patients without available tumor sam-
ples, as patients with EGFR mutation-positive ctDNA, regard-
less of mutation subtype, had a similar ORR to patients with 
EGFR mutation-positive tumors (76.9% and 69.8%, respec-
tively). A study of 50 samples (32 pleural fluid; 18 plasma) 
from Chinese patients with NSCLC previously treated with 
EGFR TKIs (line of therapy not stated) also found that an 
EGFR mutation-positive status detected by these surrogate 
samples was a significant and consistently good indicator of 
response to EGFR TKIs (pleural fluid-positive ORR 81.3% 
with direct sequencing, 72.7% with ARMS; plasma-positive 
ORR 80.0% with ARMS).15
It is widely accepted that there are challenges in EGFR 
mutation testing practice. In the past, this has been particu-
larly evident in the Asia-Pacific region, where a lack of access 
and/or adoption of testing was a barrier to large-scale testing.26 
A 2011 consensus meeting to discuss EGFR mutation testing 
in East Asia considered tissue acquisition and pre-test sample 
evaluation as important steps to increase specificity and sensi-
tivity and to thus help standardize mutation test methodology in 
the region.26 Data generated from large-scale studies of EGFR 
mutation frequency, such as the PIONEER study,27 are con-
firming that large-scale testing across countries is feasible, can 
be standardized, and can result in a high analysis success rate. 
It is hoped that data generated from ongoing diagnostic studies 
such as ASSESS16 and IGNITE17 will add to this growing body 
TABLE 3. EGFR Mutation Status Comparisons for Plasma 1 
vs Plasma 2 Circulating-Free Tumor DNA Samples by EGFR 
Mutation Status Summary and Concordance (Screened 
Patients Evaluable for Both Samples, n = 224)
Plasma 2 EGFR 
Mutation Status, n
TotalPositive Negative
Plasma 1 EGFR mutation status, n
  Positive 63 5 68
  Negative 2 154 156
  Total 65 159 224
n Rate, %
95% Confidence 
Interval
Concordance 224 96.9 93.7–98.7
EGFR, epidermal growth factor receptor.
TABLE 4. EGFR Mutation Status Comparisons for Plasma 1  
vs Plasma 2 Circulating-Free Tumor DNA Samples by EGFR 
Mutation Status Summary by EGFR Mutation Subtype 
(Screened Patients Evaluable for Both Samples, n = 224)
Plasma 2, n
Total
Positive: Exon 19 
Deletions
Positive: 
L858R Negative
Plasma 1, n
  Positive: exon 19 
deletions
43 0 4 47
  Positive: L858R 0 20 1 21
  Negative 1 1 154 156
Total 44 21 159 224
EGFR, epidermal growth factor receptor.
1352 Copyright © 2014 by the International Association for the Study of Lung Cancer
Douillard et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014
of evidence. In addition, patient monitoring through ctDNA 
testing during treatment and at progression might provide 
important information on progression mechanisms. Our lim-
ited series of 12 patients showed that in one case a resistance 
mutation (T790M) was identified. Such information might 
be useful for managing patients with progression. The issue 
of re-biopsy at progression is presently a major concern and 
ctDNA testing could potentially be an alternative approach, as 
recently published28 and more generally discussed.29
A challenge for those undertaking testing is that muta-
tion detection kits are often validated solely on tumor-derived 
DNA. In the future, kits for use on surrogate sample types 
such as cytology or plasma may become available as the body 
of evidence increases. As many patients with NSCLC attend-
ing clinic do not have tumor tissue samples available (10–15% 
from author’s clinical experience), this could limit the number 
of patients able to benefit from the current mutation testing 
environment. Progress is being made, however, as highlighted 
by the Chinese State Food and Drug Administration’s recent 
approval for the clinical use of three ADx-ARMS mutation 
tests (including EGFR) produced by Amoy Dx (Xiamen, 
China) for testing of fresh, frozen, and paraffin-embedded 
tissue as well as blood and plasma samples, so addressing 
the current area of unmet need in patients with unevaluable/
unavailable tumor samples at diagnosis.
A conundrum challenging the NSCLC community is the 
apparent lack of detectable mutations in the ctDNA of some 
patients. As noted above, the EGFR mutation detection rate in 
the study reported here was 13.7% in tumor DNA and 10.5% in 
matched ctDNA; it is unclear whether this (commonly reported) 
lower detection rate in ctDNA is due to patient biology (tumor 
heterogeneity or biologic evolution of the disease) or technical 
limitations of current technologies (sampling, extraction, and 
mutation detection). To help minimize any ctDNA false-negative 
results due to technical difficulties, a highly sensitive mutation 
detection kit should be used, for example, ARMS technology,15 
or one of the new more sophisticated techniques, for example, 
Beads, Emulsions, Amplification, and Magentics (BEAMing) or 
digital PCR. Indeed, the use of ARMS technology in the study 
reported here helped to achieve a 94.3% concordance and 65.7% 
sensitivity between matched tumor and plasma samples.
In light of these challenges/gaps in current knowledge, 
coupled with the unmet medical need in diagnosis, it is hoped 
that the results of this study, in conjunction with data from 
ongoing studies, will help to inform the NSCLC community 
about several aspects of mutation testing, including the use of 
sample types in diagnostic practice which are surrogates of 
tumor tissue when tissue is unavailable; EGFR mutation test 
processes and methodology; the use of multiple sample types 
in the assessment of EGFR mutation status; and the impact 
TABLE 5.  Median PFS for Patients With Tumor and Plasma 1 Circulating-Free Tumor DNA Samples Overall and by EGFR 
Mutation Subtypes (FAS Population)
Median PFS
Tumor (FAS, n = 106) Plasma 1 ( n = 65)
PFS Events, n Median PFS, mo 95% CI PFS Events, n Median PFS, mo 95% CI
All mutations 61 9.7 8.5–11.0 36 10.2 8.5–12.5
Exon 19 deletions 41 9.6 8.0–11.0 25 10.3 8.5–12.4
L858R point 
mutations
19 NC NC 11 NC NC
CIs were estimated using the Wilson score method.
PFS, progression-free survival; EGFR, epidermal growth factor receptor; FAS, full analysis set; CI, confidence interval; NC, not calculated.
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FIgURE 3.  Objective response rate accord-
ing to EGFR mutation (and subtype) status 
for patients who were tumor EGFR mutation 
positive, tumor and plasma 1 EGFR mutation 
positive, and tumor EGFR mutation posi-
tive and plasma EGFR mutation negative. 
Reproduced, in part, from Douillard et al.17 
Br J Cancer 2014;110:55–62.
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of EGFR mutation status on therapy choice. These data may 
help drive improvements in the EGFR mutation testing envi-
ronment, ensuring that patients have access to testing and are 
treated appropriately on the basis of the molecular features of 
their disease. To date, there are no published guidelines for the 
use of ctDNA for EGFR mutation analysis in the absence of 
NSCLC tumor samples. Such a lack of formal direction has 
necessitated clinicians to either limit the use of this sample type 
to the research setting or form their own clinical perspective/
opinion on the use of surrogate samples to ascertain mutation 
status. Therefore, although tumor tissue should be considered 
the preferred sample type for mutation analysis when available, 
the encouraging results from ctDNA analysis reported here may 
in the future help to address this current area of unmet need for 
those patients who do not have a tumor tissue sample, that is, 
their sample is unavailable or exhausted during diagnosis.
In summary, the high concordance, specificity, and sen-
sitivity reported here between DNA and ctDNA EGFR muta-
tion status demonstrates that EGFR mutation status can be 
accurately assessed using ctDNA. Although these results are 
encouraging and suggest that plasma is a suitable substitute for 
mutation analysis regardless of mutation subtype, tumor tissue 
should be considered the preferred sample type when available.
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